Abstract
The recently described complication of late and very late stent thrombosis with coronary stents has raised the question of when is it safe to stop antiplatelet therapy in the era of drug eluting stents? With several million patients having already had coronary stents implanted worldwide, the importance of an appreciation of stent thrombosis is not only critical to the cardiologist but also surgeon, physician, dentist and other specialists that perform procedures on patients which require with-holding antiplatelet agents. Currently there is great concern amongst medical professionals on how to manage this group of patients in the absence of clear guidelines. This article reviews the current data on coronary stents, in-stent restenosis and stent thrombosis and role of antiplatelet medication post percutaneous coronary intervention (PCI) to provide a concise and clear algorithm for managing perioperative antiplatelet therapy in patients having undergone recent PCI. The algorithm encourages a multidisciplinary approach and is based on the surgical bleeding risk, operative risk of adverse cardiac events and stent thrombosis risk to guide safe practice. Challenging areas including aspirin and clopidogrel hypersensitivity, clopidogrel resistance and concomitant vitamin K antagonist therapy are also addressed.
Current Drug Targets
Title: Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
Volume: 10 Issue: 6
Author(s): Brendan Bell, Darren Walters and Christian Spaulding
Affiliation:
Abstract: The recently described complication of late and very late stent thrombosis with coronary stents has raised the question of when is it safe to stop antiplatelet therapy in the era of drug eluting stents? With several million patients having already had coronary stents implanted worldwide, the importance of an appreciation of stent thrombosis is not only critical to the cardiologist but also surgeon, physician, dentist and other specialists that perform procedures on patients which require with-holding antiplatelet agents. Currently there is great concern amongst medical professionals on how to manage this group of patients in the absence of clear guidelines. This article reviews the current data on coronary stents, in-stent restenosis and stent thrombosis and role of antiplatelet medication post percutaneous coronary intervention (PCI) to provide a concise and clear algorithm for managing perioperative antiplatelet therapy in patients having undergone recent PCI. The algorithm encourages a multidisciplinary approach and is based on the surgical bleeding risk, operative risk of adverse cardiac events and stent thrombosis risk to guide safe practice. Challenging areas including aspirin and clopidogrel hypersensitivity, clopidogrel resistance and concomitant vitamin K antagonist therapy are also addressed.
Export Options
About this article
Cite this article as:
Bell Brendan, Walters Darren and Spaulding Christian, Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents, Current Drug Targets 2009; 10 (6) . https://dx.doi.org/10.2174/138945009788488413
DOI https://dx.doi.org/10.2174/138945009788488413 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Skin Tests for the Exploration of Hypersensitivity Reactions Associated
with Iodinated Contrast Media
Current Drug Safety Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Occupational Allergy in Healthcare Workers
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacogenomics of Asthma
Current Pharmaceutical Design The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Structure-based Virtual Screening of Natural Compounds as Potential Anti-Allergy Agents Against Cytokine Alarmins (TSLP and IL-33)
Letters in Drug Design & Discovery Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
Current Enzyme Inhibition Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Backbone-Cyclized Peptides: A Critical Review
Current Topics in Medicinal Chemistry Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach
Current Vascular Pharmacology Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Adenovirus Vectors and Subviral Particles for Protein and Peptide Delivery
Current Gene Therapy Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery Editorial [Hot Topic:Mimetic Peptides in Allergy and Inflammation Treatment (Guest Editor: Demitrios H. Vynios)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial (Hot Topic: Inflammation, Coagulation, Vascular Permeability and Thrombosis)
Current Vascular Pharmacology Renin-angiotensin System Blockade at the Level of the Angiotensin Converting Enzyme or the Angiotensin Type-1 Receptor: Similarities and Differences
Current Topics in Medicinal Chemistry Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology ADR in Journals: Are They Translated into Regulatory Frameworks?
Current Drug Safety Classic Histamine H1 Receptor Antagonists: A Critical Review of their Metabolic and Pharmacokinetic Fate from a Birds Eye View
Current Drug Metabolism